Literature DB >> 32079684

SGLT2 Inhibitors Produce Cardiorenal Benefits by Promoting Adaptive Cellular Reprogramming to Induce a State of Fasting Mimicry: A Paradigm Shift in Understanding Their Mechanism of Action.

Milton Packer1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32079684     DOI： 10.2337/dci19-0074

Source DB:  PubMed          Journal:  Diabetes Care        ISSN： 0149-5992            Impact factor:   19.112


× No keyword cloud information.
  39 in total

1.  Impact of an SGLT2-loss of function mutation on renal architecture, histology, and glucose homeostasis.

Authors:  Corey B Hughes; George M Mussman; Phil Ray; Robert C Bunn; Virgilius Cornea; Kathryn M Thrailkill; John L Fowlkes; Iuliana Popescu
Journal:  Cell Tissue Res       Date:  2021-01-06       Impact factor: 5.249

Review 2.  Sodium-Glucose Cotransporter 2 Inhibitors and Cardiac Remodeling.

Authors:  Husam M Salah; Subodh Verma; Carlos G Santos-Gallego; Ankeet S Bhatt; Muthiah Vaduganathan; Muhammad Shahzeb Khan; Renato D Lopes; Subhi J Al'Aref; Darren K McGuire; Marat Fudim
Journal:  J Cardiovasc Transl Res       Date:  2022-03-15       Impact factor: 4.132

Review 3.  Emerging roles of Sodium-glucose cotransporter 2 inhibitors in Diabetic kidney disease.

Authors:  Tian Gan; Yi Song; Feng Guo; Guijun Qin
Journal:  Mol Biol Rep       Date:  2022-08-24       Impact factor: 2.742

4.  Cardiovascular and renal efficacy and safety of sodium-glucose cotransporter-2 inhibitors in patients without diabetes: a systematic review and meta-analysis of randomised placebo-controlled trials.

Authors:  Wan-Chuan Tsai; Shih-Ping Hsu; Yen-Ling Chiu; Ju-Yeh Yang; Mei-Fen Pai; Mei-Ju Ko; Yu-Kang Tu; Kuan-Yu Hung; Kuo-Liong Chien; Yu-Sen Peng; Hon-Yen Wu
Journal:  BMJ Open       Date:  2022-10-14       Impact factor: 3.006

Review 5.  Renoprotective Effects of SGLT2 Inhibitors.

Authors:  Volker Vallon
Journal:  Heart Fail Clin       Date:  2022-10       Impact factor: 2.828

6.  Mapping the single-cell transcriptomic response of murine diabetic kidney disease to therapies.

Authors:  Haojia Wu; Romer Gonzalez Villalobos; Xiang Yao; Dermot Reilly; Tao Chen; Matthew Rankin; Eugene Myshkin; Matthew D Breyer; Benjamin D Humphreys
Journal:  Cell Metab       Date:  2022-06-15       Impact factor: 31.373

Review 7.  Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function.

Authors:  Volker Vallon; Subodh Verma
Journal:  Annu Rev Physiol       Date:  2020-11-16       Impact factor: 19.318

Review 8.  Emerging Pharmacologic Therapies for Heart Failure With Reduced Ejection Fraction.

Authors:  Ammar G Chaudhary; Fadi M Alreefi; Mohammad A Aziz
Journal:  CJC Open       Date:  2021-02-01

9.  Canagliflozin protects against sepsis capillary leak syndrome by activating endothelial α1AMPK.

Authors:  Sandrine Horman; Christophe Beauloye; Marine Angé; Julien De Poortere; Audrey Ginion; Sylvain Battault; Mélanie Dechamps; Giulio G Muccioli; Martin Roumain; Johann Morelle; Sébastien Druart; Thomas Mathivet; Luc Bertrand; Diego Castanares-Zapatero
Journal:  Sci Rep       Date:  2021-07-01       Impact factor: 4.379

Review 10.  NAFLD and cardiovascular diseases: a clinical review.

Authors:  Philipp Kasper; Anna Martin; Sonja Lang; Fabian Kütting; Tobias Goeser; Münevver Demir; Hans-Michael Steffen
Journal:  Clin Res Cardiol       Date:  2020-07-21       Impact factor: 5.460
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.